The FDA granted fast track designation to urcosimod to treat neuropathic corneal pain, according to a press release from Okyo Pharma. Urcosimod, formerly called OK-101, is a “lipid conjugated chemerin ...

What if there were a fabric that, like Superman, could take a bullet and self-heal? Such a super-dynamic, action-powered ...

Real-time CMXRF measurements track transition metal deposition in NMC lithium-ion batteries, crucial for improving ...

Leading global ophthalmology CRO Ora announces participation in ARVO 2025, including 2 podium presentations and 10 accepted ...

OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular condition associated with chronic ...

"Life Sciences Drive Fluorescence Microscopy Market Growth Amid Rising Disease Prevalence and Technological Advances" BOSTON, April 30, 2025 /PRNewswire/ -- According to the latest study ...

According to the latest study from BCC Research, the "Global Fluorescence Microscopy Market" is expected to grow from $968.5 ...

Urcosimod phase 2 trial treating Neuropathic Corneal Pain ("NCP”) patients was initiated in October 2024 and designed as a ...

Gabriel Filippelli, Aradhna Tripati, and Seath Brook Ahrens are this year’s Distinguished Alumni Award recipients for the ...

In a study published in Science Advances, a research team led by Prof. Liu Chengbo from the Shenzhen Institutes of Advanced ...

Acoustic stimulation affects cell development and gene activity, revealing potential applications in biotechnology and ...

This study presents glycan-coated magnetic nanoparticles as a novel tool for quick detection of foodborne pathogens, ...